Aim Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy. Patients and methods 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected. The variable number of tandem repeats (VNTR) and the single nucleotide polymorphism (SNP) in the 5′untranslated region of the TS gene were genotyped.
Introduction
5-Fluorouracil (5-FU) is the chemotherapeutic drug of choice in the treatment of colon cancer. 5-FU causes cell death through two different mechanisms [1] . One mechanism is incorporation of fluorouracil triphosphate (FUTP) into RNA causing disruption of normal RNA processes. The second mechanism of action consists on inhibition of thymidylate synthase (TS). TS provides the sole de novo source of thymidylate for DNA synthesis, thus TS inhibition causes depletion of nucleotides disrupting DNA synthesis and repair. Besides, it also causes DNA damage through misincorporation of deoxyuracil triphosphate (dUTP) into the DNA strand [1] . The fact that enhanced TS protein expression has been described as a mechanism of acquired 5-FU resistance [2] supports the thesis that TS inhibition is the main mechanism of action of 5-FU.
Because of its role as potential main target of 5-FU, TS has been widely studied as a molecular maker of therapy response in colorectal cancer, without conclusive results. Several studies have focussed on quantitation of TS protein by immunohistochemistry (IHC) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] or mRNA expression [8, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] in tumors and metastasis whereas others have focussed on gene polymorphisms genotyping [6, 11, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Besides technical differences, heterogeneity in patient selection also plays a role in the lack of consistency between results. Many studies for instance have included patients with rectal cancer [26, 32, 33, 38] , while these are treated differently than colon cancer. Furthermore some reports described heterogeneous cohorts of patients including all disease stages and patients who did not receive 5-FU based adjuvant therapy at all [24, 26, 32, 37, 38] . Results are therefore frequently contradictory [40] .
We have recently reported the reliability of different methods for TS typing, like genotyping of three known gene polymorphisms (see Fig. 1 ), TS protein expression quantitation, TS gene amplification and loss of heterozygosity in predicting 5-FU therapy response [41] . From these results, it seemed that genotyping of the 5′untraslated region polymorphism of the TS gene was more reliable for predicting response to therapy than protein expression, as determined by IHC and than genotyping the rest of polymorphisms in the 3′UTR.
The aim of this study was to determine the value of the TS gene 5′UTR polymorphisms as a possible molecular marker for 5-FU response in a well defined, homogeneous population of stage III colon cancer patients who had been treated with 5-FU based adjuvant chemotherapy.
Materials and methods

Patients
All patients (n=251) were stage III colon carcinoma patients treated with surgery followed by 5-FU based adjuvant chemotherapy between 1995 and 2004 in four different hospitals in the Eindhoven area in the south of the Netherlands.
Two hundred forty two patients (96.4%) received 5-FU in combination with levamisol following the Mayo regime, 4 patients (1.6%) had 5-FU plus leucovorin and finally 5 patients (2%) received capecitabine.
Routine histopathological diagnoses were performed in a central laboratory, the PAMM laboratory for Pathology in Eindhoven. Epidemiological data and tumor characteristics of all patients included were extracted from the Eindhoven Cancer Registry of the Comprehensive Cancer Centre South (IKZ, the Netherlands). Follow up information was obtained from the medical records of these patients. The research protocol was approved by the Scientific Committee of the Catharina Hospital Eindhoven.
VNTR typing
DNA was obtained after proteinase K digestion of 5 sections of 5 μm from formalin fixed paraffin embedded (FFPE) blocks with normal colonic tissue. Subsequently, the tissue digest was purified with HPPTP purification kit for genomic DNA (Roche diagnostics, Almere, the Netherlands). PCR for the VNTR was performed using the following primers: (forward) 5′gcg gaa ggg gtc ctg cca3′ and (reverse) 5'tcc gag ccg gcc aca ggc at3'. The Fig. 1 Schematic representation of the TYMS gene with known polymorphisms in 5' untranslated region (5'UTR) and 3' UTR. On the 5'UTR the 28 bp repeat with the SNP in the third repeat. On the 3'UTR a 6 bp long deletion/insertion reaction was performed in 50 μL final volume as described elsewhere [42] .PCR products were separated by electrophoresis on a 2% agarose gel. The expected product sizes were 107 bp for the 2R allele and 135 bp for the 3R allele.
SNP genotyping
Subsequently, the previously obtained PCR products were digested by HaeIII restriction enzyme during 1 h at 37°C (New England Biolabs, Ipswich, United Kingdom). The G to C base change removes a HaeIII restriction site present at position 12 of the second 28 bp repeat of the 3R allele. PCR products of carriers of the G allele will be digested giving an additional shorter band of 66 bp after gel electrophoresis on a 3% agarose gel.
Statistical analysis
Statistical analyses were performed using SPSS software package for Windows (Chicago, Il., U.S.A.). Categorical data were analyzed by means of a chi-square or Fischer's exact test. To study the difference in median age between the different VNTR and SNP genotype groups, age was used as a continuous variable to perform a Kruskal-Wallis test. After this, age at diagnosis was categorized according to tertiles for further analyses.
To study the effects of the different polymorphisms on 5-FU response, survival analysis was used.
The univariate survival analysis was performed using the Kaplan Meier test. Differences between survival curves were tested for significance by the Log-rank test. Overall survival was the time between surgery and death discriminating between death because of colon cancer or because of other reasons when this was specified in the medical records. Disease free survival was the time between surgery and disease progression. Disease specific survival was defined as the time between surgery and death because of colon cancer. Cox proportional hazards regression analysis was used for multivariate survival analyses. All tests were two-tailed and p<0.05 was considered to be statistically significant.
Results
Clinicopathological characteristics
Patient and tumor histopathological characteristics are shown in Table 1 . All patients had positive lymph nodes and no recognizable distant metastasis at time of diagnosis. 10 patients (4%) developed distant metastasis within the first 4 months following surgery.
Median follow-up was 47 months (range 2-133 months). 122 patients (49%) were still alive at the end of the follow up period, 30 patients (12%) were alive but had had disease progression, 80 (32%) died due to cancer related causes and 17 patients (7%) died due to non cancer related causes according to the medical records. Finally, medical records of two patients were incomplete and their follow-up status was unknown.
VNTR distribution
VNTR distribution and association with studied variables is shown in Table 1 . Distribution of the VNTR in the population studied followed Hardy Weinberg equilibrium. There was a significant association between tumor T stage and VNTR alleles. Patients homozygous for the 2R allele had significantly more frequently low T stages than did heterozygous and homozygous 3R (p=0.05).
There was, further, a significant association between age at diagnosis and the three genotypes. Median age in the group with the 3R/3R genotype was significantly lower than median age in the 2R/2R and in the 2R/3R group; 61 years vs. 64 and 65 respectively (H=14.633 p=0.001 99%CI 0.000-0.001).
To further study the association between age at diagnosis and genotypes and their role in survival, we categorize age in three different groups according to tertiles. These tertile groups corresponded in our study population to the following age categories; younger than 60 years, between 60-67 years, and older than 67 years, respectively. There was a significant relationship between the three genotypes and the three age categories (p=0.02).
SNP distribution
Two hundred and thirteen out of 251 patients had enough PCR product available to study the G > C SNP present in the second repeat of the 3R allele.
Frequencies of the different SNP alleles in our patient population were in agreement with the in the literature published frequencies and are shown in Table 2 . There was no significant association between the different SNP alleles and any of the categorical variables tested.
Age was tested as a continuous variable and there was a significant association with the SNP genotypes (H=15.135 p=0.01 99%CI 0.006-0.01). Median age in the 3 G/3 C group was 53,5 years, whereas all the other genotype groups had a median age greater than 60 years (Fig. 2) . When age was categorized according to tertiles, a positive trend was seen towards an association between age tertiles and the SNP (p=0.06).
Categorization into high and low TS expression
Based on the effects of the VNTR in TS protein expression as described in the literature, our patient population was divided in two putative categories low and high TS expression, according to the genotypes found: homozygous 2R and carriers of the 3R allele (3R/3R, 2R/3R), respectively [30, 31, 34, 42, 43] .
When additionally the SNP genotypes were included, patients can be divided in the following groups: putative high TS expression as carriers of the G allele (3RG/3RG, 3RG/ 3RC, 2R/3RG) and putative low TS expression as carriers of the C allele plus the 2R homozygous (2R/2R, 2R/3RC, 3RC/ 3RC). 60% of the patients were categorized as putative low expression vs. 40% putative high expression.
Survival analysis
Analysis of the total population revealed no associations between the genotypes, either independently or in categories (as low and high expression), and overall survival, disease free survival or cancer specific survival (Figure 3a and b) . These results were confirmed by a multivariable Cox proportional hazard model including the following variables; T stage, N stage, differentiation grade, sex, tumor location and TS SNP category or VNTR category.
Mean time to progression in the groups according to SNP and VNTR category did not differ significantly (SNP category low 42 months and high 44 months. VNTR category low 42 months and high 42 months).
Since there was an association between TS gene polymorphisms and age, we stratified to age tertiles to study the effect of the polymorphism on survival in relation to age. As shown in Fig. 4 , there was a difference between old and young patients. Moreover, this difference could be seen when we classified the patients as putative low and putative high TS expression according to the SNP (Fig. 4a) and to the VNTR alone (Fig. 4b) . There was a switch in the genotype associated to longer overall survival as the patients age increased. In other words, among patients younger than 60 years, the 2R homozygous had a better overall survival (p=0.02) whereas between patients older than 67 years, the ones with putative high TS expression (G allele) had a longer overall survival (p=0.06). These age dependent relations were also seen for CSS albeit not significant. However, there was no age dependent effect for DFS.
Discussion
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14 (30) 11 (28) 14 (39) 3 (25) 3 (21) (33) 11 (23) 1 (8) 4 (20) Fig. 4 Kaplan Meier curves of the effects on overall survival of the VNTR and SNP categories stratified to age tertiles. a SNP category b VNTR category Fig. 3 Kaplan Meier schemas for OS, DFS, and CSS according to a SNP categories TS low (2R homozygous plus C allele) and high (G allele) producers b VNTR categories (2R/2R low vs. 2R/3R and 3R/3R high) [40] , the results are often contradictory and inconclusive particularly in patients treated adjuvantly. Therefore this study aimed to elucidate the value of TS gene polymorphisms as possible molecular marker of therapy response in stage III colon carcinoma patients treated with adjuvant 5-FU chemotherapy.
In our well defined population of stage III colon cancer patients, TS genotype as determined by the SNP and the VNTR on the 5'UTR of the gene had no effect on patient outcome. There were no differences in survival (OS, DFS, CSS) between patients according to the genotypes independently or categorized as high en low TS expression based on either the TS SNP or on the VNTR alone ( Fig. 3a  and b) . Although, in a previous publication we reported a predictive value for the VNTR [41] , only a small number of patients were studied at that time and the apparently contradictory results could be explained by the difference in patient numbers between studies. In the present larger cohort of patients, we were not able to reproduce our previous results.
Moreover, inconsistent results over the predictive value of TS genotype and phenotype are a common feature in the literature. To our knowledge, there are at least, seven reports studying the value of both 5'UTR polymorphisms, VNTR and SNP, in colorectal carcinoma [6, 31-33, 35, 44, 45] . Our study agrees with Lecomte In contrast with our patient population which consisted in stage III colon carcinoma patients only, all the previous publications included rectal carcinomas and studied either advanced colorectal cancer [33, 35] or combined different disease stages [6, 32, 45] . We excluded rectal cancer patients because their treatment differs greatly from that of colon cancer patients. Rectal and colon cancer are likely to be two different diseases arising from different pathogenetic pathways and with different clinical behaviours [46] . We, as Prall et al included only stage III patients in order to have a homogeneous population. Accordingly, similar results were found although Prall and co workers included rectal cancer patients, albeit not neoadjuvantly treated and their patients' population was smaller [44] .
Several authors have described a functional role of the TS 5'UTR polymorphisms on TS protein expression. 3R allele and G allele carriers would have a higher TS protein level than homozygous 2R/2R or C allele carriers [30, 31, 34, 42, 43] . A higher TS expression has been described as a mechanism of 5-FU resistance [2] , hence one would expect that 3R allele and G allele carriers would respond worse to 5-FU and have a poorer survival. Our results do not support this thesis. However, the regulation of TS expression and function remains quite complex and most likely is influenced by many still unknown factors [2, 47] .Thus, ideally to explain the biological role of TS in the resistance to 5-FU, other techniques to objectively study protein expression and preferably function, would probably be more accurate. Therefore, our results based on DNA genotyping should not be interpreted as a biological explanation of 5-FU resistance mechanisms but as an answer to whether genotyping is a good marker for therapy response in colon cancer patients.
Interestingly, in our population, age seems to play a role on the TS genotype distribution and appears to modify the effects of the genotypes on survival. Indeed, the allelic distribution of both polymorphisms varied depending on age: the median age of the 3RC/3RG genotype was significantly lower in comparison to other genotypes. Similar results have been already reported by Odin et al. The authors described an inverse correlation between TS gene expression and age in colon cancer patients [48] . This relationship could point to a role of the TS gene polymorphisms in colon cancer risk. Hubner et al described a decreased risk of colon carcinoma between homozygotes for the TS 1491del6 on the 3'UTR of the gene. However, these authors did not find any role of the polymorphisms on the 5' UTR [49] . However, further research is needed to study the allelic distribution in the normal population and to see whether this link remains significant.
Furthermore, the effect of the TS genotypes on overall survival was also modified by age. There was a switch in the TS genotypes associated to longer overall survival as age increased. In other words, genotypes associated with low TS expression (homozygous 2R and the carriers of the C allele) had a significant positive effect on survival among patients in the first age tertile category (corresponding to patients younger than 60 years). Conversely, these genotypes had a negative effect on survival among patients in the third age tertile category (i.e. older than 67 years). In the literature, an inverse association between TS gene expression, and age in colon cancer patients was already described by Odin et al, but the authors did not report its impact on survival.
To elucidate the underlying reasons of this age-dependent relation exceeds the scope of this paper and needs additional research. Nevertheless, there is increasing evidence that age affects normal colonic mucosa and tumors. For instance, DNA methylation has been shown to increase with age in normal colonic mucosa [50, 51] and different protein expression patterns have been found in the colonic mucosa of the elderly compared to that of younger people [52] . Moreover, Morris et al have also shown that the molecular aberrations in tumors differ according to age [53] . Thus, our finding supports the hypothesis that age probably modifies the effects of different molecular pathways on oncogenesis and on cancer progression.
In conclusion, the TS polymorphisms in the 5'UTR are not good markers of 5-FU therapy response in this population of stage III colon carcinoma patients. However, further research is necessary to study the role of age as an effect modifier of the polymorphisms on survival.
